Andre Esteva, PhD

Co-Founder & CEO, Artera.
Previously: Head of Medical AI, Salesforce | Stanford AI | Google Research

[Andre Esteva, PhD @AndreEsteva]

Hey @Tesla your latest SSD is both terrible and dangerous

[Andre Esteva, PhD @AndreEsteva]

DoorDash needs to do a better job of training its drivers in the use of car GPS systems

[Nathan Silberman @NCSilberman]

Are open source pathology models ready for the clinic? Despite significant progress - not quite yet! These models show increased accuracy on retrospective datasets but struggle to deal with real-world variation as outlined on the @arteraAI tech blog: https://t.co/1Py9Y97Sv2

[Elon Musk @elonmusk]

Absolutely true

[Andre Esteva, PhD @AndreEsteva]

Founder mode is really just Extreme Ownership (credit @jockowillink ) and should be practiced by everyone, not just the founders

[Andre Esteva, PhD @AndreEsteva]

@arteraAI receives @TIME's 2024 Best Inventions Award, for the creation of our multi-modal AI platform that can personalize treatment for cancer patients. https://t.co/kMcVtXsEaT

[Andre Esteva, PhD @AndreEsteva]

TSA + CLEAR is somehow slower than TSA alone. Baffling. Paying extra to go slower is the opposite of product market fit. 🧐

[ArteraAI @arteraAI]

ICYMI: Artera's own @TimShowalter1 was joined by pathologist Adam Cole in an educational webinar sharing how the #ArteraAI Prostate Test works, how it can benefit patients with localized #prostatecancer, & how to start ordering the test. Learn more: https://t.co/jU7wMCQBT8

[Andre Esteva, PhD @AndreEsteva]

The @arteraAI Prostate Cancer Test can now inform active surveillance treatment decisions for low-risk patients. To propel adoption, we've integrated with @PathNetLab - a fully digital pathology lab that serves about 10% of the annual US prostate cancer volume across 200+ clinics in 27 states. Our test report will now be delivered with immediate turnaround time to clinicians - at the same time as the diagnostic pathology report. This is in addition to being the only predictive test in the @NCCN guidelines, and being reimbursed by @MedicareGov .

About 40% of localized prostate cancer patients are NCCN low-risk. In these patients the key clinical decision that needs to be made is whether to put them on active surveillance or active treatment. And if you don't need treatment, you certainly don't want to be placed on it. Artera's test has been updated to help inform clinicians and patients whether they would benefit from active treatment vs surveillance.

It is a privilege to work with @PathNetLab and its founder Adam Cole to support prostate cancer patients at scale.

Interested clinicians can order our test at https://t.co/oDEohZ2orR

#prostatecancer #digitalpathology #arteraai #biomarkers #AI #machinelearning #biomarkers #medicalAI

https://t.co/Bg6y1nb6QF

[Jason Scharf @Jason_A_Scharf]

Boomtown: Austin’s Next Startup Surge in Life Sciences with Jim Breyer (@jimihendrixlive), Thomas Cahill, @AndreEsteva, Jay Hartzell (@JCHartzell), & Claudia Lucchinetti (@LucchinettiMD)

Not the next SV or Boston, the first Austin!

What’s Next?

@UTAustin @DellMedSchool #sxsw

[UT Austin @UTAustin]

Join us at #UTatSXSW to learn about the next big wave of innovation: life sciences. Recent advances in AI and other technologies have supercharged these fields that will change our lives.

https://t.co/BDpd3Dy6Ze

#TexasAI | @SXSW

[Andre Esteva, PhD @AndreEsteva]

Moreover, it was included based on a Category 2A recommendation, signifying uniform consensus amongst the NCCN expert panel that our test is appropriate for prostate cancer patients.

[Andre Esteva, PhD @AndreEsteva]

ArteraAI Announced as the First-and-Only Predictive Test for Therapy Personalization in the 2024 NCCN Guidelines for Prostate Cancer

NCCN guidelines are widely considered the gold standard for clinical practice in oncology.

https://t.co/QO0WXsQbLA

[Andre Esteva, PhD @AndreEsteva]

It has the highest number of clinical endpoints of any test (distant metastasis, biochemical recurrence, prostate cancer-specific mortality), and it is only one of two tests with level 1B evidence, according to the Simon Criteria.

[Andre Esteva, PhD @AndreEsteva]

@ID_AA_Carmack This was literally my PhD thesis. With an app. We published it in @Nature https://t.co/oCas4bWCwG

[Andre Esteva, PhD @AndreEsteva]

The infusion of this additional funding is a crucial catalyst, propelling ArteraAI forward in its mission to personalize cancer therapy through AI-enabled predictive and prognostic tests. We are committed to ushering in the era of democratized precision medicine.

[Andre Esteva, PhD @AndreEsteva]

@arteraAI has raised an additional $20M in capital from some of the longest-term and deepest-pocketed investors in the world. We welcome @Prosperity7VC, the growth fund of Saudi Arabia's @aramco, and Singapore's sovereign wealth fund @singapore_edb .

https://t.co/LyLbpLVcd1

[Andre Esteva, PhD @AndreEsteva]

We were also joined by @wilsonsonsini, @TheTriumGroup, as well as individual investors @NavinChaddha (@MayfieldFund ), @rkhemani, and Andrew Tan & Elliott Tan. @walden_catalyst & @lip_bu continued their investment from prior rounds.

[Andre Esteva, PhD @AndreEsteva]

A key value that Artera brings to the table is identifying whether or not patients benefit from therapy intensification.

[Andre Esteva, PhD @AndreEsteva]

In Psychology Today, @arteraAI Chief Medical Officer @TimShowalter1 discusses how AI-driven cancer care can improve mental well-being.

#artificialintelligence #machinelearning #biomarkers #cancer #mentalhealth
https://t.co/ibRbh5BTz3

[Andre Esteva, PhD @AndreEsteva]

Patients with high-risk cancer face an elevated risk of depression and suicide. Complicating matters is the fact that more intense therapies lead to worse side effects, but do not always lead to better outcomes.